title: Neuropharmacological profile of non-peptide neurotensin antagonists.
abstract: Neurotensin, an endogenous peptide widely distributed throughout the brain, fulfils neurotransmitter criteria. When administered centrally, neurotensin induces various effects and modulates the activity of the mesolimbic dopamine system. It antagonizes the behavioural action of dopamine in a manner similar, but not identical, to antipsychotic drugs. Neurotensin is even considered to be an endogenous neuroleptic. In fact, microinjection of neurotensin elicits different effects depending on both the dose and the cerebral structures into which the injection is made. Our work on the development of orally-active neurotensin antagonists has led to the identification of SR 48692, the first non-peptide antagonist of the neurotensin receptor, and some analogues. This small molecule reveals a surprising neuropharmacological profile. It antagonizes turning behaviour induced in mice and rats (after striatal or ventral tegmental area administration of neurotensin, respectively), hypolocomotion induced by intracerebroventricular injection of neurotensin in rats, and reverses the inhibitory effect of neurotensin (nucleus accumbens injection) on amphetamine-induced hyperlocomotion in rats. However, SR 48692 cannot reverse either dopamine release in the nucleus accumbens evoked by neurotensin injection in ventral tegmental area, or hypothermia and analgesia induced by intracerebroventricular injection of neurotensin. As direct and indirect dopamine agonists have been reported to promote neurotensin release in the cortex, behavioural studies were performed using injection of apomorphine. In these experiments, SR 48692 inhibited only turning and yawning. It did not antagonize other apomorphine-dependent effects such as climbing, hypothermia, hypo- or hyperlocomotion, penile erection and stereotypies. All together, these data raise the question of the existence of neurotensin receptor subtypes and confirm that the nature of neurotensin and dopamine interactions depends on the brain structures considered.
authors.affiliation: Sanofi Recherche, Toulouse, France.
authors.forename: D
authors.initials: D
authors.lastname: Gully
authors.forename: F
authors.initials: F
authors.lastname: Jeanjean
authors.forename: M
authors.initials: M
authors.lastname: Poncelet
authors.forename: R
authors.initials: R
authors.lastname: Steinberg
authors.forename: P
authors.initials: P
authors.lastname: Soubrié
authors.forename: G
authors.initials: G
authors.lastname: Le Fur
authors.forename: J P
authors.initials: JP
authors.lastname: Maffrand
mesh_terms: D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D002491:Central Nervous System Agents / Q000494:pharmacology*; D006801:Humans; D009420:Nervous System / Q000187:drug effects*; D009496:Neurotensin / Q000037:antagonists & inhibitors*
chemical_list: D002491:Central Nervous System Agents; D009496:Neurotensin